Skin Biopsy Market Research, 2031
The global skin biopsy market size was valued at $101.2 million in 2021, and is projected to reach $181.6 million by 2031, growing at a CAGR of 6% from 2022 to 2031. Skin biopsy is a technique used in diagnosis of skin cancer and other skin disorders including actinic keratosis, dermatitis, psoriasis, and others. Skin biopsy involves removal of skin sample from the skin lesion or skin infection, and then analyzing it under the microscope for the detection of cancerous cells. This technique not only act as a diagnostic tool for skin cancer but also sometimes may assist in treatment of cancer by complete removal of cancerous cells. Furthermore, the technique is less invasive in nature and thus causes small incisions to the skin which requires less recovery time. Thus, there is a huge adoption of this technique for the diagnosis of skin cancer, due to the advantages offered by skin biopsy.
Market dynamics
The growth of the skin biopsy market size is expected to be driven by high potential in untapped, emerging markets, due to availability of improving healthcare infrastructure, increase in unmet healthcare needs, rise in prevalence of skin cancer cases, and surge in demand for advanced healthcare facilities. In addition, increase in prevalence of skin cancer cases is driving the growth of the market. In past decade, there is a huge rise in cancer cases around the globe owing to various factors including the change in lifestyle and environmental conditions.
Moreover, rise in skin cancer cases will subsequently increase the demand for skin biopsy as a diagnostic procedure and drive skin biopsy market growth. For instance, according to American Academy of Dermatology Association, more than 1 million Americans were living with melanoma as of 2022 and it is also estimated that 197,700 new cases of melanoma, 97,920 noninvasive and 99,780 invasive, were diagnosed in the U.S. in 2022. This highlights the estimated increase in skin cancer cases in U.S. in coming years, which increases the demand for skin biopsy for diagnosis purpose. Also, more people receive skin cancer diagnoses each year in U.S. than all other cancers combined, including breast, prostate, lung, and colon cancer. This drives the growth the skin biopsy market.
In addition, increase in prevalence of various skin disorders, also propels the growth during skin biopsy market forecast. Skin conditions such as skin cancer, actinic keratosis, dermatitis, psoriasis, skin infection and others can be diagnosed using skin biopsy procedure. Thus, increase in number of cases of these mentioned skin conditions, will also increase the demand for skin biopsy and also rise the demand for skin biopsy products.
Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries. This is anticipated to drive the market during the forecast period.
Though several factors boost the growth of skin biopsy market, factors such as high cost associated with the procedure provides hindrance to the growth of the market. Also, lack of awareness about advanced diagnostic techniques in developing regions such as Asia-Pacific and LAMEA, also acts as a restraint to the market. On the other hand, technological advances and new product innovations and its launch and approval in the market is anticipated to drive the market during the forecast period.
Furthermore, the outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The global skin biopsy industry experienced a decline in 2020 due to global economic recession led by COVID-19. In addition, the COVID-19 outbreak disrupted the supply chain across various end-user industries like food & beverage, healthcare, and industrial.
In addition, number of skin biopsy procedures also decreased due to factors such as decreased early detection of diseases, due to the public health regulations and social distancing. There was also a decrease in access to primary health care and specialist care along with lack of transportation services which caused hindrance to the growth of the market during the pandemic. In addition, patients also refused to seek care and treatment for skin cancers due to increased risk of corona virus infection. However, the skin biospy industry is anticipated to witness recovery after regularization of the supply chain post pandemic, and show stable growth in the coming future.
Segmental Overview
The global skin biopsy market is segmented into type, indication, end user and region. By type, the market is categorized into shave biopsy, punch biopsy, and excisional biopsy. On the basis of indication, the market is segregated into skin cancer, actinic keratosis, dermatitis, and others. On the basis of end user, the market is categorized into hospitals and clinics, diagnostic laboratories and others. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
By type, the market is segmented into shave biopsy, punch biopsy, and excisional biopsy. The punch biopsy segment dominated the global market in 2021, and is expected to grow at a highest CAGR during the forecast period, owing to increase in adoption of biopsy punches for skin cancer detection and advancements in biopsy punches for more accurate diagnosis. In addition, key market players are focusing on creating advanced biopsy punches which are easy to use and affordable. Moreover, wide range of products are offered by major key players in skin biopsy field which is anticipated to drive the market during the forecast period.
By Type
The Punch Biopsy segment was highest contributor to the market in 2021.
By indication, the market is segregated into skin cancer, actinic keratosis, dermatitis, and others. The skin cancer segment dominated the global market in 2021, and is anticipated to continue this trend during the forecast period owing to increase in prevalence of skin cancer and for early diagnosis of skin conditions. Also, skin cancer needs to be identified and treated as early as possible, to avoid the chances of surgery in the case of a serious melanoma or other skin cancer. Thus, for this early diagnosis of skin cancer, skin biopsy procedure is adopted which further increases the demand for skin biopsy devices and instruments which propels the growth of the market.
By Indication
The Skin cancer segment dominated the market in 2021 and is anticipated to grow at the highest CAGR during the forecast period.
By End User, the market is classified into hospitals & clinics, diagnostic laboratories and others. The hospitals and clinics segment held the largest market share in 2021, owing to high higher capacity for both outpatients and inpatients for cancer treatment. On the other hand, diagnostic laboratories is expected to remain dominant throughout the forecast period, owing to the increase in number of diagnostic centers around the globe.
By region, the skin biopsy market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major skin biopsy market share in 2021, and is expected to maintain its dominance during the forecast period. In regional analysis, the U.S. dominated the market in 2021, and Canada is expected to grow at the fastest rate during the forecast period.
Presence of several major players, such as Integra Lifesciences, Becton, Dickinson and Company, Innovia Medical and others is driving the market growth in North America. Moreover, advancement in manufacturing technology of skin biopsy products by the companies in this region is anticipated to drive the growth of the market during the forecast period. In addition, rise in prevalence of skin cancer cases in U.S. and other major countries is the major factor for increasing the demand for skin biopsy instruments and equipment in North America. Moreover, people in this region are more conscious about skin health and thus, the region has a greater number of patients visit hospitals for skin cancer diagnosis, which rises the demand for skin biopsy instruments which drives the market growth.
On the other hand, Asia-Pacific expected to grow at the highest rate during the forecast period. On the basis of regional analysis, Rest of Asia-Pacific dominated the market in Asia-pacific region, and India is anticipated to grow at the fastest rate during the forecast period. The market growth in this region is attributable to the presence of pharmaceutical companies in the region as well as growing purchasing power of populated countries, such as China and India. Moreover, increase in awareness regarding skin health and its diagnosis and treatment procedures in the population is anticipated to drive the market during the forecast period.
COMPETITION ANALYSIS
Competitive analysis and profiles of the major players in the skin biopsy market, such as AccuTec, Inc., Becton, Dickinson and Company, Cardinal Health, Innovia Medical (DTR Medical Ltd), Integra LifeSciences, Jai Surgicals Ltd., Kai Group, Paramount Surgimed Ltd., Verna care and World Precision Instruments (WPI) are provided in this report. There are some important players in the market such as Aesthetic Group, Schuco. and others. Major players have adopted business expansion, branding and acquisition as key developmental strategies to improve the product portfolio of the skin biopsy market.
Some examples of business expansion in the market
In June 2020, Innovia Medical announced the increase in manufacturing capacity of cervical rotating biopsy punch to meet increased cancer diagnosis.
Acquisitions in the market
In October 2019, Innovia Medical announced the acquisition of DTR Medical which is based in Swansea, Wales, and UK. DTR Medical specializes in the design and manufacture of Single-use surgical instruments for general and specialist surgical procedures.
Branding in the market
In December 2019, Innovia Medical announced that 88% of Clinicians recommended the DTR Medical Biopsy Punch to a colleague as a result of its high performance and effectiveness, which highlights its increasing demand in the market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the skin biopsy market analysis from 2021 to 2031 to identify the prevailing skin biopsy market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the skin biopsy market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global skin biopsy market trends, key players, market segments, application areas, and market growth strategies.
Skin Biopsy Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 181.6 million |
 Growth Rate | CAGR of 6% |
 Forecast period | 2021 - 2031 |
 Report Pages | 245 |
 By Type |
|
 By Indication |
|
 By End User |
|
 By Region |
|
 Key Market Players | Jai Surgicals Ltd., KAI Group, Innovia Medical, Vernacare, AccuTec, Inc., Paramount Surgimed Limited, Integra LifeSciences, Becton, Dickinson and Company, Cardinal Health Inc., World Precision Instruments |
Analyst Review
The increase in demand for advanced diagnostic procedures for skin disorders is expected to offer profitable opportunities for the expansion of the market. Also, increase in adoption of skin biopsy by patients is attributed to the technological advancements in the diagnostic field and various strategies adopted by the key market players.
Increase in skin cancer cases in developed and developing regions has largely contributed toward the market revenue in 2021, and is expected to maintain this trend throughout the forecast period. Also, rise in awareness around the globe regarding skin biopsy as a diagnostic technique and its advantages, increases its demand in the healthcare sector and thus, significantly contributes toward the revenue generation. Moreover, increase in prevalence of other skin conditions such as dermatitis, actinic keratosis, and other skin infection, is projected to boost the growth of the market.
Furthermore, North America is expected to witness highest growth, in terms of revenue, owing to increase in awareness among the people regarding management of skin health and rise in government initiatives promoting awareness drives, lead to the growth of the market. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in investments for manufacturing of skin biopsy instruments and devices and upsurge in healthcare expenditure in the emerging economies such as India and China.
Asia-Pacific is expected to witness highest growth rate at a CAGR of 7.3% for the skin biopsy market throughout the forecast period, owing to investments by public and private market players in this field, presence of high population base and untapped market opportunities.
Punch Biopsy segment dominated the global market in 2021, owing to several advantages and applications of punch biopsy over excitional and shave biopsy and also owing to the increase in prevalence of skin cancer.
Top companies such as AccuTec, Inc., Becton, Dickinson and Company, Cardinal Health, Innovia Medical (DTR Medical Ltd), Integra LifeSciences, Jai Surgicals Ltd., Kai Group, Paramount Surgimed Ltd., Verna care and World Precision Instruments (WPI) hold the market share in skin biopsy market.
Factors such as increase in incidences of skin cancer in developed and developing regions, increase in awareness among the population about skin biopsy and rise in adoption of minimally invasive approaches are driving the market growth.
The forecast period for skin biopsy market is 2022 to 2031.
The base year is 2021 in skin biopsy market.
The market value of skin biopsy market in 2022 is $107.47 million.
The total market value of skin biopsy market is $101.2 million in 2021.
Skin biopsy is an examination of skin cells which involves removal of cells and tissues from the skin or lesions and further observing it under microscope.
Loading Table Of Content...
